View in EDS HTML Full Text PDF Full Text

Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.

Saved in:
Bibliographic Details
Title: Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.
Authors: Chelliah V; Certara UK Ltd., Sheffield, UK., Lazarou G; Certara UK Ltd., Sheffield, UK., Bhatnagar S; Abbvie Inc., North Chicago, Illinois, USA., Gibbs JP; Abbvie Inc., North Chicago, Illinois, USA., Nijsen M; Abbvie Inc., North Chicago, Illinois, USA., Ray A; Abbvie Inc., North Chicago, Illinois, USA., Stoll B; Abbvie Inc., North Chicago, Illinois, USA., Thompson RA; Abbvie Inc., North Chicago, Illinois, USA., Gulati A; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Tokyo or Tsukuba-shi, Japan., Soukharev S; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Tokyo or Tsukuba-shi, Japan., Yamada A; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Tokyo or Tsukuba-shi, Japan., Weddell J; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Tokyo or Tsukuba-shi, Japan., Sayama H; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Tokyo or Tsukuba-shi, Japan., Oishi M; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Tokyo or Tsukuba-shi, Japan., Wittemer-Rump S; Bayer AG, Leverkusen, Germany., Patel C; Bayer AG, Leverkusen, Germany., Niederalt C; Bayer AG, Leverkusen, Germany., Burghaus R; Bayer AG, Leverkusen, Germany., Scheerans C; Bayer AG, Leverkusen, Germany., Lippert J; Bayer AG, Leverkusen, Germany., Kabilan S; EMD Serono, Merck KGaA, Billerica, Massachusetts, USA., Kareva I; EMD Serono, Merck KGaA, Billerica, Massachusetts, USA., Belousova N; EMD Serono, Merck KGaA, Billerica, Massachusetts, USA., Rolfe A; EMD Serono, Merck KGaA, Billerica, Massachusetts, USA., Zutshi A; EMD Serono, Merck KGaA, Billerica, Massachusetts, USA., Chenel M; Servier, Suresnes, France., Venezia F; Servier, Suresnes, France., Fouliard S; Servier, Suresnes, France., Oberwittler H; Servier, Suresnes, France., Scholer-Dahirel A; Servier, Suresnes, France., Lelievre H; Servier, Suresnes, France., Bottino D; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA., Collins SC; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA., Nguyen HQ; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA., Wang H; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA., Yoneyama T; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA., Zhu AZX; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA., van der Graaf PH; Certara UK Ltd., Sheffield, UK., Kierzek AM; Certara UK Ltd., Sheffield, UK.
Source: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Mar; Vol. 109 (3), pp. 605-618. Date of Electronic Publication: 2020 Aug 14.
Publication Type: Journal Article; Review
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32686076
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chelliah+V%22">Chelliah V</searchLink>; Certara UK Ltd., Sheffield, UK.<br /><searchLink fieldCode="AU" term="%22Lazarou+G%22">Lazarou G</searchLink>; Certara UK Ltd., Sheffield, UK.<br /><searchLink fieldCode="AU" term="%22Bhatnagar+S%22">Bhatnagar S</searchLink>; Abbvie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Gibbs+JP%22">Gibbs JP</searchLink>; Abbvie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Nijsen+M%22">Nijsen M</searchLink>; Abbvie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Ray+A%22">Ray A</searchLink>; Abbvie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Stoll+B%22">Stoll B</searchLink>; Abbvie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Thompson+RA%22">Thompson RA</searchLink>; Abbvie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Gulati+A%22">Gulati A</searchLink>; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Tokyo or Tsukuba-shi, Japan.<br /><searchLink fieldCode="AU" term="%22Soukharev+S%22">Soukharev S</searchLink>; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Tokyo or Tsukuba-shi, Japan.<br /><searchLink fieldCode="AU" term="%22Yamada+A%22">Yamada A</searchLink>; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Tokyo or Tsukuba-shi, Japan.<br /><searchLink fieldCode="AU" term="%22Weddell+J%22">Weddell J</searchLink>; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Tokyo or Tsukuba-shi, Japan.<br /><searchLink fieldCode="AU" term="%22Sayama+H%22">Sayama H</searchLink>; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Tokyo or Tsukuba-shi, Japan.<br /><searchLink fieldCode="AU" term="%22Oishi+M%22">Oishi M</searchLink>; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Global Development Inc./Astellas Pharma Inc., Tokyo or Tsukuba-shi, Japan.<br /><searchLink fieldCode="AU" term="%22Wittemer-Rump+S%22">Wittemer-Rump S</searchLink>; Bayer AG, Leverkusen, Germany.<br /><searchLink fieldCode="AU" term="%22Patel+C%22">Patel C</searchLink>; Bayer AG, Leverkusen, Germany.<br /><searchLink fieldCode="AU" term="%22Niederalt+C%22">Niederalt C</searchLink>; Bayer AG, Leverkusen, Germany.<br /><searchLink fieldCode="AU" term="%22Burghaus+R%22">Burghaus R</searchLink>; Bayer AG, Leverkusen, Germany.<br /><searchLink fieldCode="AU" term="%22Scheerans+C%22">Scheerans C</searchLink>; Bayer AG, Leverkusen, Germany.<br /><searchLink fieldCode="AU" term="%22Lippert+J%22">Lippert J</searchLink>; Bayer AG, Leverkusen, Germany.<br /><searchLink fieldCode="AU" term="%22Kabilan+S%22">Kabilan S</searchLink>; EMD Serono, Merck KGaA, Billerica, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Kareva+I%22">Kareva I</searchLink>; EMD Serono, Merck KGaA, Billerica, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Belousova+N%22">Belousova N</searchLink>; EMD Serono, Merck KGaA, Billerica, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Rolfe+A%22">Rolfe A</searchLink>; EMD Serono, Merck KGaA, Billerica, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Zutshi+A%22">Zutshi A</searchLink>; EMD Serono, Merck KGaA, Billerica, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Chenel+M%22">Chenel M</searchLink>; Servier, Suresnes, France.<br /><searchLink fieldCode="AU" term="%22Venezia+F%22">Venezia F</searchLink>; Servier, Suresnes, France.<br /><searchLink fieldCode="AU" term="%22Fouliard+S%22">Fouliard S</searchLink>; Servier, Suresnes, France.<br /><searchLink fieldCode="AU" term="%22Oberwittler+H%22">Oberwittler H</searchLink>; Servier, Suresnes, France.<br /><searchLink fieldCode="AU" term="%22Scholer-Dahirel+A%22">Scholer-Dahirel A</searchLink>; Servier, Suresnes, France.<br /><searchLink fieldCode="AU" term="%22Lelievre+H%22">Lelievre H</searchLink>; Servier, Suresnes, France.<br /><searchLink fieldCode="AU" term="%22Bottino+D%22">Bottino D</searchLink>; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Collins+SC%22">Collins SC</searchLink>; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Nguyen+HQ%22">Nguyen HQ</searchLink>; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Wang+H%22">Wang H</searchLink>; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Yoneyama+T%22">Yoneyama T</searchLink>; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Zhu+AZX%22">Zhu AZX</searchLink>; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22van+der+Graaf+PH%22">van der Graaf PH</searchLink>; Certara UK Ltd., Sheffield, UK.<br /><searchLink fieldCode="AU" term="%22Kierzek+AM%22">Kierzek AM</searchLink>; Certara UK Ltd., Sheffield, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220372741%22">Clinical pharmacology and therapeutics</searchLink> [Clin Pharmacol Ther] 2021 Mar; Vol. 109 (3), pp. 605-618. <i>Date of Electronic Publication: </i>2020 Aug 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0372741 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-6535 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200099236%22">00099236 </searchLink><i>NLM ISO Abbreviation: </i>Clin Pharmacol Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32686076
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cpt.1987
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 605
    Titles:
      – TitleFull: Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chelliah V
      – PersonEntity:
          Name:
            NameFull: Lazarou G
      – PersonEntity:
          Name:
            NameFull: Bhatnagar S
      – PersonEntity:
          Name:
            NameFull: Gibbs JP
      – PersonEntity:
          Name:
            NameFull: Nijsen M
      – PersonEntity:
          Name:
            NameFull: Ray A
      – PersonEntity:
          Name:
            NameFull: Stoll B
      – PersonEntity:
          Name:
            NameFull: Thompson RA
      – PersonEntity:
          Name:
            NameFull: Gulati A
      – PersonEntity:
          Name:
            NameFull: Soukharev S
      – PersonEntity:
          Name:
            NameFull: Yamada A
      – PersonEntity:
          Name:
            NameFull: Weddell J
      – PersonEntity:
          Name:
            NameFull: Sayama H
      – PersonEntity:
          Name:
            NameFull: Oishi M
      – PersonEntity:
          Name:
            NameFull: Wittemer-Rump S
      – PersonEntity:
          Name:
            NameFull: Patel C
      – PersonEntity:
          Name:
            NameFull: Niederalt C
      – PersonEntity:
          Name:
            NameFull: Burghaus R
      – PersonEntity:
          Name:
            NameFull: Scheerans C
      – PersonEntity:
          Name:
            NameFull: Lippert J
      – PersonEntity:
          Name:
            NameFull: Kabilan S
      – PersonEntity:
          Name:
            NameFull: Kareva I
      – PersonEntity:
          Name:
            NameFull: Belousova N
      – PersonEntity:
          Name:
            NameFull: Rolfe A
      – PersonEntity:
          Name:
            NameFull: Zutshi A
      – PersonEntity:
          Name:
            NameFull: Chenel M
      – PersonEntity:
          Name:
            NameFull: Venezia F
      – PersonEntity:
          Name:
            NameFull: Fouliard S
      – PersonEntity:
          Name:
            NameFull: Oberwittler H
      – PersonEntity:
          Name:
            NameFull: Scholer-Dahirel A
      – PersonEntity:
          Name:
            NameFull: Lelievre H
      – PersonEntity:
          Name:
            NameFull: Bottino D
      – PersonEntity:
          Name:
            NameFull: Collins SC
      – PersonEntity:
          Name:
            NameFull: Nguyen HQ
      – PersonEntity:
          Name:
            NameFull: Wang H
      – PersonEntity:
          Name:
            NameFull: Yoneyama T
      – PersonEntity:
          Name:
            NameFull: Zhu AZX
      – PersonEntity:
          Name:
            NameFull: van der Graaf PH
      – PersonEntity:
          Name:
            NameFull: Kierzek AM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2021 Mar
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1532-6535
          Numbering:
            – Type: volume
              Value: 109
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Clinical pharmacology and therapeutics
              Type: main
ResultId 1